Investor Presentaiton

Key strengths and capabilities Collaboration across business units Industry leading product Deep market presence development skills Early mover advantage in Biosimilars Vertically integrated organization with modern infrastructure • Several niche product opportunities (decitabine, azacitidine, fondaparinux) first to market in USA • Branded generic markets - India, Russia), CIS countries and Venezuela Generic markets - USA, UK and Germany . First to launch Biosimilar rituximab in 2007 • 4 Biosimilar products being marketed • Investor Presentation - 2016 R&D centers in India, UK, Netherlands and US 20 USFDA inspected formulation & API manufacturing facilities Dr. Reddy's Laboratories Ltd. 12

View entire presentation